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Background: It is suggested that vitamin D deficiency is associated with cardiovascular disease (CVD) via its effect
on lipid profiles. The objective of this study was to determine the association between fasting serum levels of
25(OH) D and lipid profiles in patients with type 2 diabetes.
Methods: This cross-sectional study was conducted on 108 type 2 diabetics. Patients were selected randomly among
members of the Iranian Diabetes Association according to study criteria. Fasting concentration of 25(OH) D, calcium,
phosphorus, parathyroid hormone (PTH) and lipid profiles (including triglyceride (TG), high-density lipoprotein (HDL),
low-density lipoprotein (LDL), and total cholesterol) were measured.
Results: The mean serum levels of 25-hydroxyvitamin D (25(OH) D) and PTH were 53.41 ± 33.25 nmol/l and 40.24 ±
18.24 pmol/l, respectively, in type 2 diabetic patients. Prevalence of vitamin D deficiency was 58.34% and vitamin D
sufficiency and insufficiency combined was 41.66%. Although in diabetic patients with vitamin D deficiency, serum
levels of total cholesterol, TG, and LDL were higher and HDL was lower compared to patients with vitamin D sufficiency,
this association was statistically significant only for serum level of TG (145.91 ± 79.00 vs. 122.95 ± 55.82 mg/dl).
Conclusions: The results of present study show that serum concentrations of 25(OH) D were inversely associated with
TG. More interventional studies are needed to confirm the relationship between serum concentration of vitamin D and
lipid profile in patients with type 2 diabetes.
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The incidence of type 2 diabetes mellitus (T2DM), a com-
mon chronic and non-communicable disease, is increasing
at an alarming rate worldwide [1]. The World Health
Organization (WHO) predicts that the global prevalence
of type 2 diabetes will increase from 171 million people
in 2000 to 366 million in 2030 [2]. T2DM is associated
with a high risk of cardiovascular disease, blindness, ne-
phropathy, and neuropathic complications [3,4]. The Iran
Multi-Center Osteoporosis Study has estimated the preva-
lence of mild, moderate, and severe vitamin D deficiency
as 47.2%, 45.7%, and 44.2% in the age groups <50, 50–60,
and ≤60 years, respectively among women, and 54.2%,
41.2%, and 37.5%, respectively among men in the same
age groups. Vitamin D is a fat soluble vitamin with well-* Correspondence: ehsaneh_taheri@yahoo.com
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Research carried out over recent decades indicates that
vitamin D deficiency plays an important role in many
non-skeletal diseases [5] such as hypertension [6], CVD
[7,8], type 1 and 2 diabetes [8], immune disorders, osteo-
porosis, and cancers [9]. The vitamin D receptor (VDR) is
found within various tissues and the α1-hydroxy enzyme
(which converts 25-hydroxyvitamin D (25(OH) D) to 1,
25-(OH) 2-D, the active form of vitamin D) is found lo-
cally [10].
Many cross-sectional and interventional studies have
demonstrated that vitamin D deficiency is associated with
impaired glucose tolerance and diabetes mellitus [11-13].
Therefore, serum concentrations of 25(OH) D are lower in
T2DM patients compared with healthy controls. There are
several mechanisms proposed to explain the inverse rela-
tionship between vitamin D and type 2 DM. Vitamin D,
via both genomic and non-genomic pathways, has direct
and indirect effects on insulin secretion, β-cell function,Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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vascular disease is the most common cause of mortality
in type 2 DM. Researchers have confirmed that vitamin D
plays an important role in endothelial function, blood pres-
sure control, calcification of the coronary vasculature, in-
creased vascular resistance, and prevention of CVD [16].
The effect of vitamin D on regulation of the lipid profile
is one of the proposed mechanisms for the relationship
between vitamin D deficiency and CVD. The aim of our
study is to determine the association between serum level
of vitamin D and lipid profiles, including serum concentra-
tions of cholesterol, TG, HDL, and LDL, in type 2 diabetic
patients.
Methods
In this cross-sectional study, 108 type 2 diabetic patients
with age of 20–80 years from the Iranian Diabetes Associ-
ation and National Iranian Oil Company (NIOC) - Central
Hospital were selected via random sampling. Exclusion cri-
teria included pregnancy, lactation, use of drugs affecting
the lipid profile or calcium and bone metabolism, chronic
disorders of the liver or kidney, endocrinology disorders
such as hypo- or hyperthyroidism and hyperparathyroid-
ism, smoking, insulin injection, use of anticonvulsive drugs,
and vitamin D or calcium supplementation. To decrease
the seasonal variability in biochemical determinations, our
sampling was performed between April and June. A writ-
ten consent form (approved by the Ethics Committee of
Tehran University of Medical Sciences) was signed by all
participants. After overnight fasting, 10 ml of peripheral
blood was withdrawn. Blood samples were centrifuged at
3000 rpm for 10 min and stored at −20°C. Serum levels of
25(OH) D were measured using the Chemiluminescence
Immune Assay method or CLIA (Diasorin, Stillwater, MN)
[17], which measures both 25 hydroxyD2 and D3 vitamin
D. The normal range of 25(OH) was 6–54 ng/ml (15-
135 nmol/l) using this method. Serum levels of PTH were
measured using an RIA kit (CIS Biointernational, France)
with a normal reference range of 8–79 pg/ml. Serum cal-
cium and phosphorus levels were analyzed using a Pars
Azmoon kit (Pars Azmoon Co., Tehran, Iran). Normal
ranges of calcium and phosphorus were defined as 8.6–
10.3 mg/dl and 2.5–5.0 mg/dl, respectively. Fasting serum
glucose was measured using glucose-oxidase with a Pars
Azmoon kit (Pars Azmoon Co., Tehran, Iran) and serum
insulin was measured using a radioimmunoassay method
(Biosorce kit, Denmark). HbA1C was determined using
Nyco CardReader ІІ analyzer according the procedure
provided [18]. Plasma total cholesterol, HDL-C, and tri-
glyceride concentrations were measured in duplicate using
enzymatic kits, standardized reagents, and standards (Pars
Azmoon Co., Tehran, Iran). LDL-C concentration was cal-
culated using the Friedewald equation [19]. Anthropomet-
ric data including weight and height were measured usinga Seca scale (Seca 725; GmbH & Co., Hamburg, Germany)
with subjects wearing light clothes and no shoes. Weight
and height were measured to the nearest 100 g and
0.5 cm, respectively. Body mass index (BMI) was defined
as weight (kg) divided by height squared (m2). A 25(OH)
D level of less than 50 nmol/L was considered as vitamin
D deficiency and levels of equal and more than 50 nmol/L
as sufficient [20]. All continuous values are expressed as
mean ± SD and categorical variables are presented as per-
centage. The Student’s t-test was employed to compare
differences between the means of continuous variables.
Multiple linear regression analysis was applied to assess
the association of 25(OH) D (as independent variable) with
each component of the lipid profiles (as dependent vari-
ables) in three models: Model I, crude; Model II, adjusted
for age and gender; and Model III, additionally adjusted
for BMI. The results of linear regression are presented as
B (SE). P-values less than 0.05 were considered statistically
significant. Data were analyzed by SPSS statistical software
(version 16.0; SPSS Inc., Chicago, IL).
Results
In our study, 108 individuals with type 2 diabetes were
(50.9% men and 49.1% women) participated. The mean
serum levels of 25-hydroxyvitamin D (25(OH) D) and
PTH were 53.41 ± 33.25 nmol/l and 40.24 ± 18.24 pmol/l,
respectively in type 2 diabetic patients. The prevalence of
vitamin D deficiency was 58.34% and vitamin D sufficiency
and insufficiency combined was 41.66% in patients with
type 2 diabetes. Table 1 presents the characteristics of par-
ticipants according to vitamin D status. In general, the
mean levels of TG, FBS were significantly higher and cal-
cium was lower in diabetic patients with vitamin D defi-
ciency compared to patients with sufficient and insufficient
levels of vitamin D. Our data revealed that serum levels of
25(OH) D had an inverse, but not significant, association
with TG and total cholesterol and a positive correlation
with HDL-C and LDL-C after adjusting for confounding
variables (Table 2).
Discussion
The prevalence of vitamin D deficiency was 58.34% and
vitamin D sufficiency and insufficiency was 41.66% in
patients with type 2 diabetes. Our study findings indicate
that there is a negative, but non-significant, relationship
between serum levels of 25(OH) D and that of TG in
diabetic patients. Few studies have been carried out
on the relationship between serum levels of vitamin D
and lipid profiles. Ford and colleagues, in their NHANES
ІІІ study, found a negative association between serum
levels of 25(OH) D and TG in patients with hypertriglyc-
eridemia. However, this relationship was not observed
with regard to HDL cholesterol in healthy subjects [21].
Rejnmark and colleagues performed a study among 82
Table 1 Characteristic of participants by vitamin D status
Variable Sufficient of vitamin D vitamin D
≥ 50 nmol/L n = 45
Deficiency of vitamin D vitamin D
< 50 nmol/L n = 63
Overall n = 108 p-value
Age 47.63 ± 11.80 47.66 ± 12.38 47.65 ± 12.08 0.74
Gender (M/F) (%) 62.2/37.8 42.9/57.1 50.9/49.1 0.25
Weight (Kg) 75.95 ± 13.38 76.73 ± 13.24 76.42 ± 13.23 0.34
BMI (Kg/m2) 26.33 ± 6.99 28.73 ± 5.10 27.76 ± 6.01 0.43
FBS (mg/dl) 129.47 ± 53.38 145.92 ± 75.66 138.80 ± 67.14 0.01
HbA1c (%) 5.91 ± 1.56 6.24 ± 2.00 6.10 ± 1.82 0.10
Insulin 11.48 ± 7.98 12.51 ± 8.20 12.08 ± 8.09 0.97
Calcium (mg/dl) 9.02 ± 0.69 8.85 ± 0.55 8.96 ± 0.50 0.07
Phosphorus (mg/dl) 3.58 ± 0.36 3.66 ± 0.30 3.62 ± 0.33 0.39
PTH (pmol/l) 40.36 ± 16.48 40.16 ± 19.50 40.24 ± 18.24 0.16
Cholesterol (mg/dl) 182.00 ± 37.58 189.89 ± 43.35 186.5 ± 40.96 0.44
TG (mg/dl) 122.95 ± 55.82 145.91 ± 79.00 136.14 ± 70.68 0.01
HDL (mg/dl) 34.83 ± 8.67 34.14 ± 8.42 34.43 ± 8.49 0.85
LDL (mg/dl) 109.36 ± 32.29 113.61 ± 30.08 111.84 ± 30.93 0.71
P < 0.05 was significance.
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either 40 mg/day Simvastatin or a placebo for 1 year, in
which vitamin D, TG, and LDL levels were measured at
baseline and after 26 weeks of treatment [22]. In this study,
Simvastatin showed no effect on vitamin D status, but de-
creased the serum levels of TG and LDL. These results sug-
gest that serum concentration of TG is inversely associated
with serum level of 25(OH) D [22]. In contrast, Chiu
showed no relationship between serum levels of 25(OH) D
and TG or HDL cholesterol in healthy subjects [15].
There is only one review article that addresses the rela-
tionship between serum levels of 25(OH) D and lipids. In
this analysis, 22 cross-sectional studies and 10 placebo-
controlled interventional studies were identified in a 2009
search of PubMed [23]. In all cross-sectional studies, serum
levels of 25(OH) D were found to have a direct relationship
with HDL cholesterol. In addition, all studies reported an
inverse association between serum levels of 25(OH) D and
TG. There is no general agreement on the effects ofTable 2 Regression analysis of 25(OH) D as independent varia
Model I
B (CI 0.95) P-value‡ B (CI 0.9
TG 0.02 (−0.05 – 0.10) 0.67 −0.02 (−0.05 –
TC 0.08 (−0.31 – 0.14) 0.73 0.10 (−0.34 –
LDL-C 0.09 (−0.18 – 0.37) 0.74 0.11 (−0.18 –
HDL-C 0.19 (−0.34 – 0.73) 0.60 0.22 (−0.36 –
B: Unstandardized Coefficients, CI: Confidence Interval.
Model 1: crude.
Model 2: adjusted for age, gender.
Model 3: adjusted for age, gender, BMI.
‡: Regression test P-value.
25(OH) D: 25-hydroxy vitamin D (ng/mLTC: total cholesterol (mg/dL); HDL-C: high d
cholesterol (mg/dL); TG: triglycerides(mg/dL).25(OH) D on serum levels of TG in interventional studies
with supplementation of vitamin D. Although a positive
association was observed in some studies, other studies
showed an inverse relationship between serum levels of
25(OH) D and TG [23]. In all interventional studies on
the relationship between vitamin D and lipids, hyperlipid-
emia had been considered as inclusion criteria and none
of these studies had sufficient power to evaluate this re-
lationship. In only one study was a significant effect
seen, with an 8% (0.28 mmol/L) increase in serum LDL-C
and a 16% (0.22 mmol/L) decrease in serum TG in those
given vitamin D as compared to the placebo group [24]. It
was suggested that vitamin D has both direct and indirect
effects on modifying the lipid profile and that the effect of
vitamin D on decreasing serum levels of TG may occur
through regulatory action that increases the activity of
lipoprotein lipase in adiposity [25]. Several mechanisms
are suggested to explain the effect of calcium on lipids, in-
cluding its reducing role in fatty acid absorption via thebles and parameters of lipid profile in diabetic patients
Model II Model III
5) P-value‡ B (CI 0.95) P-value‡
0.11) 0.86 −0.03 (−0.04 – 0.11) 0.21
0.13) 0.83 0.12 (−0.32 – 0.10) 0.58
0.41) 0.87 0.12 (−0.15 – 0.39) 0.70
0.80) 0.94 0.25 (−0.31 – 0.82) 0.81
ensity lipoprotein cholesterol; LDL-C (mg/dL): low density lipoprotein
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By decreased absorption of fat, particularly saturated fatty
acids, it is expected that serum levels of total and LDL
cholesterol will be reduced [26]. In addition, calcium can
increase the conversion of cholesterol to bile acids due to
its ability to bind with bile acids [27]. However, the effect
of enteric calcium on lipid absorption is very limited, and
it does not have a significant effect on lipid profiles [28].
On the other hand, in vitro studies have demonstrated
that PTH decreases lipolysis (through increasing the level
of cytosolic calcium) [29] and increases the expression of
fatty acid synthesis [30].
Garry John and colleagues conducted a study on 170
UK Bangladeshi adults (69 men and 101 women) with
no history of diabetes or other chronic disease. Their
data showed that the serum level of 25(OH) D is an inde-
pendent predictor of fasting apolipoprotein A1. However,
no relationship was observed between 25(OH) D and TG
or HDL cholesterol [31]. Apolipoprotein A1 is an essential
part of HDL cholesterol that acts as a scavenger of choles-
terol from tissues and transports it to the liver.
Exposure to sunlight and adequate consumption of food-
stuffs naturally rich in vitamin D (liver, fatty fish, dairy pro-
ducts, and egg yolk) are the main requirements for normal
vitamin D levels in humans [32]. Dermal synthesis of vita-
min D through exposure to ultraviolet compounds from
natural sunlight can provide 80–100% of human vitamin D
requirements [33].
Dietary vitamin D is incorporated with other lipids in
chylomicrons and is absorbed via the lymphatic system.
The results of our study showed a statistically non-
significant positive association between serum levels of
25(OH) D and total and LDL cholesterol. There are sev-
eral explanations for these observations. First, the preva-
lence of vitamin D deficiency is very common in Iran,
similar to other countries in the Middle East, because of
inadequate consumption of foodstuffs rich in vitamin D
and limited exposure to sunlight (for cultural reasons)
[34]. Second, the main source of vitamin D in our country
is the consumption of animal-based foodstuffs that con-
tain other lipids in addition to vitamin D.
In our study, the maximum duration of illness was
5 years in type 2 diabetic patients. Therefore, the relation-
ship between serum levels of 25(OH) D and lipids may be
affected by increased disease duration in these patients.
According to other studies, it is suggested that vitamin
D deficiency is associated with changes in serum levels of
apolipoproteins, but not with fasting levels of lipids.
Therefore, more studies are needed to confirm the possible
effects of vitamin D on serum concentrations of lipids.
This study has some limitations, the main one being
its cross-sectional nature, with no causality effect to
report. Variation in the polymorphisms of vitamin D bind-
ing protein (DBP) and vitamin D receptor (VDR), sunlightexposure, and the effect of vitamin D supplementation on
weight gain also need to be considered.
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